Publication Name	World Journal of Gastrointestinal Oncology
Manuscript ID	38099
Country	United Kingdom

Received	2018-01-25 16:21
Peer-Review Started	2018-01-26 01:48
To Make the First Decision	2018-03-05 02:57
Return for Revision	2018-03-07 09:59
Revised	2018-03-15 15:29
Second Decision	2018-05-30 10:08
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2018-05-30 17:57
Articles in Press	2018-05-30 17:57
Publication Fee Transferred
Edit the Manuscript by Language Editor	2018-06-04 18:16
Typeset the Manuscript	2018-07-10 11:50
Publish the Manuscript Online	2018-07-15 09:50

ISSN	1948-5204 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Review
Article Title	HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer
Manuscript Source	Unsolicited Manuscript
All Author List	Hazel Lote, Nicola Valeri and Ian Chau
ORCID	Author(s) ORCID Number Hazel Lote http://orcid.org/0000-0003-1172-0372 Nicola Valeri http://orcid.org/0000-0002-5426-5683 Ian Chau http://orcid.org/0000-0003-0286-8703
Funding Agency and Grant Number
Corresponding Author	Ian Chau, FRCP (Hon), MD, MRCP, Doctor, Doctor, Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton SM2 5PT, United Kingdom. ian.chau@rmh.nhs.uk
Key Words	Human epidermal growth factor receptor 2; Gastro-oesophageal cancer; Trastuzumab; Resistance; Biomarkers; Breast cancer
Core Tip	Human epidermal growth factor receptor 2 (HER2)-inhibition is an important therapeutic strategy in HER2-amplified gastro-oesophageal cancer (GOC). A significant proportion of GOC patients display HER2 amplification, yet HER2 inhibition in these patients has not displayed the success seen in HER2 amplified brea­st cancer. We evaluate current clinical and laboratory evidence surrounding HER2 inhibition in GOC. Inher­ent differences in the HER2 receptor, signalling path­ways, associated microRNA signature and immune environm­ent may partly explain the disappointing clinical trial ou­tcomes seen in GOC. Only with improved understan­ding of HER2 inhibition can effective treatment be provided in order to improve clinical outcomes for patients.
Publish Date	2018-07-15 09:50
Citation	Lote H, Valeri N, Chau I. HER2 inhibition in gastro-oesophageal cancer: A review drawing on lessons learned from breast cancer. World J Gastrointest Oncol 2018; 10(7): 159-171
URL	http://www.wjgnet.com/1948-5204/full/v10/i7/159.htm
DOI	http://dx.doi.org/10.4251/wjgo.v10.i7.159

Full Article (PDF)	WJGO-10-159.pdf
Full Article (Word)	WJGO-10-159.doc
Manuscript File	38099-Review.docx
Answering Reviewers	38099-Answering reviewers.pdf
Audio Core Tip	38099-Audio core tip.m4a
Conflict-of-Interest Disclosure Form	38099-Conflict-of-interest statement.pdf
Copyright License Agreement	38099-Copyright assignment.pdf
Peer-review Report	38099-Peer-review(s).pdf
Scientific Misconduct Check	38099-Scientific misconduct check.pdf
Scientific Editor Work List	38099-Scientific editor work list.pdf